依奇珠单抗治疗日本红皮病型或泛发性脓疱型银屑病患者的长期疗效与安全性:开放标签3期研究(UNCOVER-J)的亚组分析
该亚组分析纳入UNCOVER-J研究中8例红皮病型银屑病和5例泛发性脓疱型银屑病患者,评估依奇珠单抗治疗至第244周的疗效与安全性。结果显示多数患者从第12周起总体改善评分达到消退或改善,PASI和皮肤症状评分早期且持续改善,DLQI和瘙痒NRS的平均改善维持至第244周,未发现新的安全性问题。
要点
- 依奇珠单抗治疗红皮病型或泛发性脓疱型银屑病,多数患者从第12周起总体改善评分达消退或改善。
- PASI和皮肤症状评分(仅泛发性脓疱型)早期且持续改善,DLQI和瘙痒NRS改善维持至第244周。
- 治疗3年耐受性良好,未发现新的安全性问题。
核心结论
- 这些发现提示依奇珠单抗可能是红皮病型或泛发性脓疱型银屑病的有效长期治疗选择。
研究设计与样本
- UNCOVER-J(NCT01624233)开放标签3期研究的亚组分析,纳入红皮病型银屑病8例和泛发性脓疱型银屑病5例日本患者。
- 患者第0周接受依奇珠单抗160 mg,至第12周每2周80 mg,此后每4周80 mg至第244周。
主要发现
- 多数患者从第12周起总体改善评分为消退或改善。
- 所有患者PASI和皮肤症状评分(仅泛发性脓疱型)早期且持续改善。
- 第12周DLQI和瘙痒NRS的平均改善维持至第244周。
- 治疗3年耐受性良好,未发现新的安全性问题。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Erythrodermic and generalized pustular psoriasis are rare, difficult to treat forms of psoriasis. In previous reports, we documented 24- and 52-week findings of an open-label, phase 3 trial (UNCOVER-J) of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis; most patients responded to treatment and maintained response through 52 weeks. OBJECTIVE: To assess the long-term (>3 years) efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis. METHODS: These subgroup analyses were of a partial population of patients from UNCOVER-J (NCT01624233; Sponsored by Eli Lilly and Company), specifically those with erythrodermic psoriasis (N = 8) or generalized pustular psoriasis (N = 5). These patients received 160 mg ixekizumab at Week 0, ixekizumab 80 mg every 2 weeks through Week 12, and ixekizumab 80 mg every 4 weeks thereafter up to Week 244. This regimen is consistent with the regimen approved in Japan for plaque, erythrodermic, and generalized pustular psoriasis and psoriatic arthritis. Efficacy assessments included Global Improvement Score (GIS), Psoriasis Area and Severity Index (PASI), dermal symptoms (for patients with generalized pustular psoriasis), Dermatology Life Quality Index (DLQI) and Itch Numeric Rating Scale (NRS). Safety assessments included treatment-emergent adverse events and adverse events of special interest. RESULTS: Most patients had a GIS of resolved or improved from Week 12 onwards, and all patients had early and sustained improvement in PASI and dermal symptom (generalized pustular psoriasis only) scores. Mean improvements in DLQI and Itch NRS at Week 12 were sustained through Week 244. Ixekizumab was well tolerated over 3 years of treatment in patients with erythrodermic psoriasis or generalized pustular psoriasis, and no new safety concerns were identified. CONCLUSION: These findings suggest that ixekizumab can be an effective long-term treatment option for erythrodermic or generalized pustular psoriasis.
引用
- Okubo Y, Mabuchi T, Iwatsuki K, et al. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J). J Eur Acad Dermatol Venereol. 2018. PMID: 30317671. doi:10.1111/jdv.15287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。